Page last updated: 2024-12-09

ethylenethiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethylenethiourea: A degradation product of ethylenebis(dithiocarbamate) fungicides. It has been found to be carcinogenic and to cause THYROID hyperplasia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2723650
CHEMBL ID11860
CHEBI ID34750
SCHEMBL ID41176
MeSH IDM0007906

Synonyms (137)

Synonym
BIDD:ER0692
AKOS000431145
smr000059087
MLS000069432 ,
ethylenethiourea
NCI60_001620
ethylene thiourea
rcra waste no. u116
4,5-dihydro-2-mercaptoimidazole
sanceller 22
vulkacit npv/c
rhodanin s 62
usaf el-62
1,3-ethylene-2-thiourea
2-thiol-dihydroglyoxaline
soxinol 22
na-22-d
l'ethylene thiouree [french]
rhenogran etu
imidazolidinethione
rodanin s-62 [czech]
rcra waste number u116
imidazoline-2(3h)-thione
n,n'-ethylenethiourea
mercazin i
vulkacit npv/c2
robac 22
akrochem etu-22
nocceler 22
4,5-dihydroimidazole-2(3h)-thione
mercozen
2-imidazoline-2-thiol
imidazoline-2-thiol
1,3-ethylenethiourea
aperochem etu-22
2-mercapto-4,5-dihydroimidazole
warecure c
pennac cra
ethylene thiouree [french]
hsdb 1643
na-22
einecs 202-506-9
tetrahydro-2h-imidazole-2-thione
mercaptoimidazoline
ai3-16292
sodium-22 neoprene accelerator
imidazole-2(3h)-thione, 4,5-dihydro-
thiourea, n,n'-(1,2-ethanediyl)-
urea, 1,3-ethylene-2-thio-
2-imidazolidimethione
nci-c03372
2-mercapto-2-imidazoline
2-merkaptoimidazolin [czech]
ccris 298
imidazoline, 2-mercapto-
2-imidazolidinethione
inchi=1/c3h6n2s/c6-3-4-1-2-5-3/h1-2h2,(h2,4,5,6
imidazolidine-2-thione
5328-35-8
NCGC00091855-01
ethylene thiourea (etu)
2-mercaptoimidazoline
96-45-7
STK369397
2-imidazolidinethione, 98%
etu ,
NCGC00091855-02
E-6500
smr000777952
ethylenethiourea (etu)
MLS002415731
CHEMBL11860
chebi:34750 ,
I0004
AKOS000120435
A845596
4,5-dihydro-1h-imidazole-2-thiol
STL131803
NCGC00091855-04
NCGC00091855-03
ethlenethiourea
24foj4n18s ,
l'ethylene thiouree
2-merkaptoimidazolin
ec 202-506-9
unii-24foj4n18s
ethylene thiouree
rodanin s-62
NCGC00258846-01
dtxsid5020601 ,
cas-96-45-7
tox21_201294
dtxcid90601
tox21_301034
NCGC00254936-01
12261-94-8
2-mercapto imidazoline
HMS2230P07
na 22
FT-0670303
2-thioxoimidazolidine
FT-0626339
1h-imidazole-2-thiol, 4,5-dihydro-
ethylene thiourea [mi]
ethylenethiourea [iarc]
ethylene thiourea [hsdb]
HMS3372A09
BP-30094
SCHEMBL41176
n,n'-ethylene thiourea
2-imidazolidine-thione
2-imidozolidimethione
akroform etu-22 pm
2-thionoimidazolidine
2h-imidazole-2-thione, tetrahydro-
perkacit etu
bdbm62876
cid_2723650
OPERA_ID_324
F0001-2297
mfcd00005276
2-imidazolidinethione, purum, >=98.0% (hplc)
2-imidazolidinethione, pestanal(r), analytical standard
EN300-21447
ethylene thiourea 10 microg/ml in acetonitrile
ethenethiourea
mancozeb tp1
Q408767
(e)-2-deoxy-2-(fluoromethylene)cytidine
STR00167
ncic03372
nci c03372
HY-W010593
cobalt(i i) nitrate
CS-W011309
n(oo(3)aaoea)
Z104497392

Research Excerpts

Overview

Ethylenethiourea (ETU) is a metabolite, environmental degradation product and minor technical impurity of the ethylenebisdithiocarbamate (EBDC) class of fungicides. It is a carcinogen, goitrogen, teratogen and a weak bacterial mutagen.

ExcerptReferenceRelevance
"Ethylenethiourea (ETU) is a major metabolite of ethylenebisdithiocarbamate pesticides: a sensitive and specific assay for its determination in human urine is proposed below. "( Application of gas chromatography-mass spectrometry for the determination of urinary ethylenethiourea in humans.
Birindelli, S; Campo, L; Colosio, C; FoĆ , V; Fustinoni, S, 2005
)
2
"Ethylenethiourea itself is a carcinogen, goitrogen, teratogen and a weak bacterial mutagen."( The effect of oxidation of the sulfur atom on the mutagenicity of ethylenethiourea.
Autio, K; Pyysalo, H; von Wright, A, 1982
)
1.22
"Ethylenethiourea (ETU) is a metabolite, environmental degradation product and minor technical impurity of the ethylenebisdithiocarbamate (EBDC) class of fungicides. "( The genetic toxicology of ethylenethiourea: a case study concerning the evaluation of a chemical's genotoxic potential.
Arce, G; Elia, MC; Hurt, SS; O'Neill, PJ; Scribner, HE, 1995
)
2.03
"Ethylenethiourea (ETU) is a decomposition product from ethylene-bis-dithiocarbamates (EBDCs), the most widely used class of fungicides in the world. "( Determination of ethylenethiourea in food commodities by a two-step derivatization method and gas chromatography with electron-capture and nitrogen-phosphorus detection.
Dubey, JK; Heberer, T; Stan, HJ, 1997
)
2.08
"Ethylenethiourea is an important degradation product of ethylenebisdithiocarbamate fungicides, which are widely used in different kinds of crops. "( Degradation of ethylenethiourea (ETU) in oxic and anoxic sandy aquifers.
Bossi, R; Jacobsen, OS, 1997
)
2.09
"Ethylenethiourea (ETU) is a thyroid carcinogen present in foods formed by degradation and metabolism of ethylenebis[dithiocarbamate] fungicides. "( Mechanism of thyroid peroxidase inhibition by ethylenethiourea.
Doerge, DR; Takazawa, RS,
)
1.83
"Ethylenethiourea (ETU) is a ubiquitous impurity of the ethylenebisdithiocarbamate (EBDC) fungicides widely used in agriculture and forestry. "( Ethylenethiourea in air and in urine as an indicator of exposure to ethylenebisdithiocarbamate fungicides.
Kurttio, P; Savolainen, K, 1990
)
3.16
"Ethylenethiourea (ETU) is a potent teratogen in the rat but not in the mouse or any other species tested. "( Difference in teratogenic potency of ethylenethiourea in rats and mice: relative contribution of embryonic and maternal factors.
Daston, GP; Heitmeyer, SA; Powers, JF; Yonker, JE, 1989
)
1.99
"Ethylenethiourea (ETU) is a specific neuroteratogen that induces communicating hydrocephalus ex vacuo at oral doses far lower than those that cause any observable toxic sign or 50% death (LD50) in the rat dam. "( Ethylenethiourea: a review of teratogenicity and distribution studies and an assessment of reproduction risk.
Khera, KS, 1987
)
3.16
"Ethylenethiourea (ETU) is a degradation product from ethylenebisdithiocarbamate such as Zineb and Maneb which have been extensively used in food crops and ornamental plants. "( Experimental production of congenital malformation of the central nervous system in rat fetuses by single dose intragastric administration of ethylenethiourea.
Hung, CF; Lee, CS; Lin, KR, 1986
)
1.91

Effects

ExcerptReferenceRelevance
"Ethylenethiourea (ETU) has been recognized as a compound with adverse toxicological properties. "( Survey of ethylenethiourea (ETU) in ethylenebis(dithiocarbamate) (EBDC) fungicides.
Camoni, I; Citti, P; Di Muccio, A; Pontecorvo, D, 1988
)
2.12

Treatment

ExcerptReferenceRelevance
"Treatment with ethylenethiourea induced morphological abnormalities in the cladoceran carapace."( An assay system for detecting environmental toxicants with cultured cladoceran eggs in vitro: malformations induced by ethylenethiourea.
Hanazato, T; Ohta, T; Shiga, Y; Tokishita, S; Yamagata, H, 1998
)
0.85

Toxicity

ExcerptReferenceRelevance
" Only those rats which received ETU at 125 or 625 ppm and those ingesting PTU or amitrole demonstrated a measurable toxic response."( Dietary subacute toxicity of ethylene thiourea in the laboratory rat.
Baron, RL; Freudenthal, RI; Kerchner, G; Persing, R,
)
0.13
" LD50 values indicate that SS, NAP, and PNP were more toxic (8."( Developmental toxicity of nine selected compounds following prenatal exposure in the mouse: naphthalene, p-nitrophenol, sodium selenite, dimethyl phthalate, ethylenethiourea, and four glycol ether derivatives.
Booth, GM; Bradshaw, WS; Carter, MW; Hardin, BD; Plasterer, MR; Schuler, RL, 1985
)
0.47
" Since ETU does not appear very potent and is not extremely toxic to test cells and organisms, it is not surprising to find that ETU does not produce consistent effects in many of the assays reviewed."( Ethylene thiourea (ETU). A review of the genetic toxicity studies.
Dearfield, KL, 1994
)
0.29
"For the last 30 years the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) has carried out toxicological evaluations and safety assessments of dithiocarbamate pesticides, continuously adjusting previous appraisals in the light of new data and advances in the understanding of the principles and mechanisms of toxic action of these compounds."( International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU--a review and update.
Almeida, WF; Burin, GJ; Jaeger, RB; Puga, FR; Rahde, AF; Reyes, FG; Schvartsman, S; Vettorazzi, G,
)
0.13
"Considerable public concern has developed regarding possible adverse reproductive outcomes resulting from exposure to power frequency magnetic fields (MF)."( Developmental toxicity study of 60 Hz (power frequency) magnetic fields in rats.
Gauger, JR; Johnson, TR; Mallett, E; McCormick, DL; Ryan, BM, 1996
)
0.29
" However, it will be necessary to quantitate toxicant-induced changes at the molecular level and to determine the level of change needed to perturb higher levels of biological organization at which adverse effects are manifested."( Advances in understanding mechanisms of toxicity and implications for risk assessment.
Daston, GP,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"Mutagenic potentials of ethylenethiourea (ETU) in combination with sodium nitrite or of N-nitroso-ETU, a nitrosation product of ETU in vitro, were investigated in the mouse dominant-lethal test."( Induction of dominant-lethal mutations after administration of ethylenethiourea in combination with nitrite of the n-nitroso-ethylenethiourea in mice.
Shingu, A; Shirasu, Y; Teramoto, S, 1978
)
0.8

Dosage Studied

Embryos were studied either after direct exposure to ethylenethiourea (ETU) during incubation of embryo cultures or after maternal ETU dosing and subsequent embryonic development in utero. Differentiation of rat midbrain cells was also inhibited by the serum samples prepared from rats or mice dosed with 200 mg/kg of ETU.

ExcerptRelevanceReference
" Dose-response experiments with intraperitoneal injection of N-nitroso-ETU revealed an apparent no-effect level of about 15--18 mg/kg."( Nitrosation in vitro and in vivo by sodium nitrite, and mutagenicity of nitrogenous pesticides.
Seiler, JP, 1977
)
0.26
" Daily dosage levels (mg/kg/day) were ETU at 0, 15, 25 and 35; DMT at 0, 15, 25, 50, 100, and 200; DBT at 0, 15, 25, 50, 100, and 200; and DPT at 0, 25, 50, 100, and 200."( Difference in the developmental toxicity of ethylenethiourea and three N,N'-substituted thiourea derivatives in rats.
de Ceaurriz, J; Langonne, I; Sabate, JP; Saillenfait, AM, 1991
)
0.54
" Differentiation of rat midbrain cells was also inhibited by the serum samples prepared from rats or mice dosed with up to 200 mg/kg of ethylenethiourea."( Species differences between rats and mice in the teratogenic action of ethylenethiourea: in vivo/in vitro tests and teratogenic activity of sera using an embryonic cell differentiation system.
Iio, T; Nakamura, A; Takahashi, A; Tsuchiya, T, 1991
)
0.72
"Embryos were studied either after direct exposure to ethylenethiourea (ETU) during incubation of embryo cultures or after maternal ETU dosing and subsequent embryonic development in utero with a view to assess the similarity of these two systems to produce hydrocephalus."( Ethylenethiourea-induced hydrocephalus in vivo and in vitro with a note on the use of a constant gaseous atmosphere for rat embryo cultures.
Khera, KS, 1989
)
1.97
" The initial target following maternal dosing with ETU is the primitive neuroblast that undergoes necrosis, but the subsequent changes leading to the development of hydrocephalus are not clear."( Ethylenethiourea: a review of teratogenicity and distribution studies and an assessment of reproduction risk.
Khera, KS, 1987
)
1.72
" In the in vivo study, ETU orally administered as a single 30 or 45 mg/kg dose to rats on day 19 of pregnancy was found to induce necrosis of neuroblasts in the fetal CNS after 18 and 24 hours of dosing and a high incidence of hydrocephalus in postnatal pups at both doses."( Neuronal degeneration caused by ethylenethiourea in neuronal monocell layers in vitro and in fetal rat brain in vivo.
Khera, KS, 1987
)
0.56
" The procedure embodies both a proper fit to experimental data and an assumption of approximate linearity of the dose-response curve in the low-dose range."( An improved procedure for low-dose carcinogenic risk assessment from animal data.
Crump, KS, 1984
)
0.27
" However, the combined dosing resulted in the elimination of almost all the anomalies."( Reduction of teratogenic effects of ethylenethiourea in rats by interaction with sodium nitrite in vivo.
Khera, KS, 1982
)
0.54
" MMI and ETU were dosed simultaneously, one hour after dosing with SKF."( Effects of pretreatment with SKF-525A, N-Methyl-2-thioimidazole, sodium phenobarbital, or methyl cholanthrene on ethylenethiourea-induced teratogenicity in rats.
Iverson, F; Khera, KS, 1981
)
0.47
" The dose-response curve fitted a linear model only between 62."( Gas chromatography-mass spectrometry determination of ethylenethiourea hemoglobin adducts: a possible indicator of exposure to ethylene bis dithiocarbamate pesticides.
Airoldi, L; Allevi, R; Fanelli, R; Meli, G; Pastorelli, R; Romagnano, S, 1995
)
0.54
" Groups of 30 males and 30 females each were given 10 weekly oral administrations of ETU and sodium nitrite with the following combinations of dosing (ETU vs sodium nitrite, mg/kg/wk): 0 vs 0, 100 vs 0, 0 vs 70, 25 vs 17."( Tumor induction by concurrent oral administration of ethylenethiourea and sodium nitrite in mice.
Harada, T; Maita, K; Yoshida, A, 1993
)
0.54
" In embryos, the concentration of ETU peaked at 30 min after dosing and disappeared at 48 hr."( Time course of ethylene thiourea in maternal plasma, amniotic fluid and embryos in rats following single oral dosing.
Akahori, F; Arishima, K; Eguchi, Y; Iwase, T; Masaoka, T; Shirai, M; Takizawa, T; Yamamoto, M, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.25930.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency37.81630.000221.22318,912.5098AID1259243; AID588516
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency1.89970.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency60.07530.001022.650876.6163AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency50.63080.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.35420.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.25300.000229.305416,493.5996AID1259383
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.25550.001628.015177.1139AID1224843; AID1224895
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency1.99530.794321.275750.1187AID624246
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency63.92240.000627.21521,122.0200AID651741; AID743202; AID743219
gemininHomo sapiens (human)Potency3.26430.004611.374133.4983AID624296
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.14960.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)195.00000.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 38Homo sapiens (human)Activity10.00000.15003.256310.0000AID1619467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 38Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 38Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID71665Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 4 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID71775Percent of untreated control cell growth evaluated in friend leukemia cells on day 3 at a concentration of 4 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID71654The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 4 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (306)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990108 (35.29)18.7374
1990's45 (14.71)18.2507
2000's66 (21.57)29.6817
2010's71 (23.20)24.3611
2020's16 (5.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.13 (24.57)
Research Supply Index5.85 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index48.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.29%)5.53%
Reviews13 (3.77%)6.00%
Case Studies1 (0.29%)4.05%
Observational0 (0.00%)0.25%
Other330 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]